Growth Metrics

Coherus Oncology (CHRS) Change in Acquisitions & Divestments (2017 - 2025)

Coherus Oncology (CHRS) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $19.8 million as the latest value for Q4 2025.

  • Quarterly Change in Acquisitions & Divestments changed N/A to $19.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.3 million through Dec 2025, up 156.68% year-over-year, with the annual reading at $21.5 million for FY2025, 147.03% up from the prior year.
  • Change in Acquisitions & Divestments hit $19.8 million in Q4 2025 for Coherus Oncology, up from $2.5 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $131.1 million in Q4 2023 to a low of -$4.2 million in Q2 2023.
  • Historically, Change in Acquisitions & Divestments has averaged $29.9 million across 4 years, with a median of $18.2 million in 2021.
  • Biggest five-year swings in Change in Acquisitions & Divestments: plummeted 91.01% in 2021 and later tumbled 64.57% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $19.0 million in 2021, then soared by 590.9% to $131.1 million in 2023, then crashed by 98.1% to $2.5 million in 2024, then soared by 696.3% to $19.8 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for CHRS at $19.8 million in Q4 2025, $2.5 million in Q3 2024, and $6.2 million in Q1 2024.